Enovis Co. (NYSE:ENOV) Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC lowered its stake in Enovis Co. (NYSE:ENOV - Free Report) by 5.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 178,741 shares of the company's stock after selling 9,420 shares during the period. Lazard Asset Management LLC owned about 0.31% of Enovis worth $7,843,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in ENOV. Hood River Capital Management LLC acquired a new stake in Enovis in the fourth quarter valued at approximately $29,024,000. Raymond James Financial Inc. acquired a new stake in shares of Enovis in the 4th quarter valued at $16,407,000. ExodusPoint Capital Management LP lifted its position in shares of Enovis by 919.4% during the 4th quarter. ExodusPoint Capital Management LP now owns 333,302 shares of the company's stock worth $14,625,000 after purchasing an additional 300,605 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of Enovis during the fourth quarter worth $10,970,000. Finally, Boston Partners grew its stake in shares of Enovis by 27.1% during the fourth quarter. Boston Partners now owns 1,048,532 shares of the company's stock worth $46,034,000 after purchasing an additional 223,816 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company's stock.

Wall Street Analyst Weigh In

ENOV has been the subject of a number of recent analyst reports. Canaccord Genuity Group decreased their price target on Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. JMP Securities cut their target price on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Finally, Needham & Company LLC lowered their price target on Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a report on Friday, May 9th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $58.00.

Enovis Stock Performance

Shares of ENOV traded down $0.44 during midday trading on Tuesday, reaching $35.04. 107,797 shares of the stock were exchanged, compared to its average volume of 776,929. The business's 50-day moving average price is $35.13 and its 200 day moving average price is $41.37. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -16.00 and a beta of 1.79. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. Enovis Co. has a twelve month low of $29.32 and a twelve month high of $52.76.

Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.81 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.07. The business had revenue of $558.83 million for the quarter, compared to analysts' expectations of $558.80 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company's quarterly revenue was up 8.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.50 EPS. On average, sell-side analysts expect that Enovis Co. will post 2.79 EPS for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.